These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 6340163)
1. Is pharmaceutical innovation declining?: interpreting measures of pharmaceutical innovation and regulatory impact in the USA, 1950-1980. Wardell WM; Sheck LE Ration Drug Ther; 1983 Jan; 17(1):1-7. PubMed ID: 6340163 [No Abstract] [Full Text] [Related]
3. Constraints on innovation in drug development and use. Lasagna L Psychopharmacol Bull; 1972 Apr; 8(2):43-50. PubMed ID: 4550369 [No Abstract] [Full Text] [Related]
4. [Clinical pharmacology in the USA. 3. Administrative measures to regulate drug research in humans]. Spechtmeyer H Med Welt; 1968 Sep; 36():1894-6. PubMed ID: 4887073 [No Abstract] [Full Text] [Related]
5. The Food and Drug Administration perspective: use of an investigational drug in a medical emergency. Schultheis LW; Rappaport BA Anesth Analg; 2007 Mar; 104(3):479-80. PubMed ID: 17312189 [No Abstract] [Full Text] [Related]
6. Pharmacogenomics. Going from genome to pill. Service RF Science; 2005 Jun; 308(5730):1858-60. PubMed ID: 15976283 [No Abstract] [Full Text] [Related]
7. Pharmacoeconomics: determining the value of drug therapy. Peterson C Healthplan; 1998; 39(3):44-50. PubMed ID: 10181751 [No Abstract] [Full Text] [Related]
8. Innovative strategies for early clinical R&D. Butz RF; Morelli G IDrugs; 2008 Jan; 11(1):36-41. PubMed ID: 18175261 [TBL] [Abstract][Full Text] [Related]
9. Experiences with GLP/GCP from the pharmaceutical industry's viewpoint. Legler UF Methods Find Exp Clin Pharmacol; 1993 May; 15(4):233-6. PubMed ID: 8361261 [TBL] [Abstract][Full Text] [Related]
10. The sources of innovation. Cooper JD Psychopharmacol Bull; 1972 Apr; 8(2):50-8. PubMed ID: 4550370 [No Abstract] [Full Text] [Related]
12. King of the pill. Pfizer is the biggest drug company ever. Can it become the best? Simons J Fortune; 2003 Apr; 147(7):94-6, 100, 102. PubMed ID: 12698860 [No Abstract] [Full Text] [Related]
13. How pharmacogenomics will impact the federal regulation of clinical trials and the new drug approval process. Binzak BA Food Drug Law J; 2003; 58(1):103-27. PubMed ID: 12739592 [No Abstract] [Full Text] [Related]
14. Biopharmaceutical statistics in a pharmaceutical regulated environment: past, present, and future. Segreti AC; Leung HM; Koch GG; Davis RL; Mohberg NR; Peace KE J Biopharm Stat; 2001 Nov; 11(4):347-72. PubMed ID: 12018784 [TBL] [Abstract][Full Text] [Related]
15. Should off-label drug use be off-the-table? Rivkees SA J Pediatr Endocrinol Metab; 2007 Feb; 20(2):171-2. PubMed ID: 17396432 [No Abstract] [Full Text] [Related]
16. Recombinant protein therapeutics--success rates, market trends and values to 2010. Pavlou AK; Reichert JM Nat Biotechnol; 2004 Dec; 22(12):1513-9. PubMed ID: 15583654 [No Abstract] [Full Text] [Related]
17. Drug development and the FDA's Critical Path Initiative. Woosley RL; Cossman J Clin Pharmacol Ther; 2007 Jan; 81(1):129-33. PubMed ID: 17186012 [TBL] [Abstract][Full Text] [Related]
18. Paediatric clinical trials: redressing the imbalance. Schreiner MS Nat Rev Drug Discov; 2003 Dec; 2(12):949-61. PubMed ID: 14654794 [No Abstract] [Full Text] [Related]
19. Realizing two-tiered innovation policy through drug regulation. Ridgway WE Stanford Law Rev; 2006 Feb; 58(4):1221-50. PubMed ID: 16685807 [No Abstract] [Full Text] [Related]